Refresh
Company Event • 09 Nov 2021 14:30 • Latest
Location:3-24-1,Takada
Toshima-ku
Japan
2nd Quarter of FY2021 Earnings Results
Speakers
- Shigeru Uehara (Executive Vice President, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Ken Uehara (Member of the Board, Taisho Pharmaceutical Holdings Co., Ltd.)
- Jun Kuroda (Member of the Board, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Osamu Kitatani (Member of the Board, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Jinsei Maruyama (Corporate Officer /Taisho Pharmaceutical Co., Ltd. Executive Officer, Taisho Pharmaceutical Holdings Co., Ltd.)
- Takeshi Ishiguro (General Manager, Finance, Taisho Pharmaceutical Holdings Co., Ltd.)
- Shinichi Tanaka (General Manager, Corporate Communication, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Noriyuki Miyata (Corporate Officer, Taisho Pharmaceutical Co., Ltd.)
- Hisashi Umeoka (Director, Taisho Pharmaceutical Co., Ltd.)
Analysts
- Kazuaki Hashiguchi (Analyst, Daiwa Securities Co. Ltd.)
- Fumiyoshi Sakai (Analyst, Credit Suisse Securities (Japan) Limited)
- Akinori Ueda (Analyst, Goldman Sachs Japan Co., Ltd.)
- Shohei Oda (Analyst, Morgan Stanley MUFG Securities Co., Ltd.)
- Kenya Matsuo (Analyst, SMBC Nikko Securities Inc.)
Company Event • 18 May 2021 13:00
Location:Japan
Financial Results Briefing for the Fiscal Year Ending March 2021
Speakers
- Akira Uehara (Chief Executive Officer, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Shigeru Uehara (Executive Vice President, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Ken Uehara (Member of the Board, Taisho Pharmaceutical Holdings Co., Ltd.)
- Shinichi Tanaka (General Manager, Corporate Communication, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.)
- Jun Kuroda (Member of the Board, Senior Executive Officer, Taisho Pharmaceutical Co., Ltd.)
- Itsumi Takahashi (Member of the Board, Executive Officer, Taisho Pharmaceutical Co., Ltd.)
- Osamu Kitatani (Executive Officer, Taisho Pharmaceutical Co., Ltd.)
Analysts
- Shohei Oda (Analyst, Morgan Stanley MUFG Securities Co., Ltd.)
- Akinori Ueda (Analyst, Goldman Sachs Japan Co., Ltd.)
- Hidemaru Yamaguchi (Analyst, Citigroup Global Markets Japan Inc.)
- Kazuaki Hashiguchi (Analyst, Daiwa Securities Co. Ltd.)
- Sakai (Analyst, Credit Suisse Securities (Japan) Limited)
Duration
- Presentation: 41 minutes
- Q&A: 41 minutes
Company Event • 30 Oct 2019 14:30
Location:3-24-1 Takada
Toshima-ku
Japan
Q2 Financial Results Briefing for the Fiscal Year Ending March 2020
Speakers
- Ken Uehara (Member of the Board, Taisho Pharmaceutical Holdings Co., Ltd.)
- Jun Kuroda (Member of the Board, Senior Executive Officer, Taisho Pharmaceutical Co., Ltd.)
- Hisashi Umeoka (Director, General Manager, the Self-Medication Business and Marketing Division, Taisho Pharmaceutical Co., Ltd.)
- Takeshi Ishiguro (General Manager, Finance, Taisho Pharmaceutical Holdings Co., Ltd.)
- Hideki Iuchi (General Manager, Corporate Communications, Taisho Pharmaceutical Holdings Co., Ltd.)
- Jinsei Maruyama (Corporate Officer, Head of Pharmaceutical Development Division, Taisho Pharmaceutical Co., Ltd.)
- Noriyuki Miyata (Corporate Officer, Deputy Chief Division Officer, Taisho Pharmaceutical Co., Ltd.)
Analysts
- Fumiyoshi Sakai (Analyst, Credit Suisse Securities (Japan) Limited)
- Akinori Ueda (Analyst, Goldman Sachs Japan Co., Ltd.)
- Hidemaru Yamaguchi (Analyst, Citigroup Global Markets Japan Inc.)
- Kazuaki Hashiguchi (Analyst, Daiwa Securities Co. Ltd.)
- Shinichiro Muraoka (Analyst, Morgan Stanley MUFG Securities Co., Ltd.)
No more events